February 2021, Drugs Monitor, Page 3

(01 Feb 2021) Tocilizumab- associated with reduced mortality and faster clinical improvement in patients with higher IL-6

February 5, 2021

Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis https://www.medrxiv.org/content/10.1101/2021.01.28.21249932v1 Patients treated with TCZ were balanced compared to non-TCZ regarding gender, age, BMI, and prevalence of coexisting conditions.… Continue reading "(01 Feb 2021) Tocilizumab- associated with reduced mortality and faster clinical improvement in patients with higher IL-6"

(30 Jan 2021) Tocilizumab- study supports the use of tocilizumab in COVID-19 ARDS patients

February 1, 2021

Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale https://doi.org/10.7759/cureus.12290 An observational study was conducted from Feb 2020 to May 2020 on COVID-19 ARDS patients with hyperinflammation. A total of 244 patients with COVID-19 were… Continue reading "(30 Jan 2021) Tocilizumab- study supports the use of tocilizumab in COVID-19 ARDS patients"

(29 Jan 2021) Corticosteroids- showed a statistically significant decrease in mortality

February 1, 2021

High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response https://doi.org/10.1371/journal.pone.0243964 HDCPT showed a statistically significant decrease in mortality (HR = 0.087 [95% CI 0.021-0.36]; P < 0.001). 30-day time course analysis of laboratory… Continue reading "(29 Jan 2021) Corticosteroids- showed a statistically significant decrease in mortality"

(28 Jan 2021) Tocilizumab- incidence of secondary nosocomial infections was high

February 1, 2021

Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain https://doi.org/10.1080/17512433.2021.1875819 162 patients (median age 64 years; 70.4% male) were included in a retrospective cohort in Spain. At time of TCZ administration, 48.1%… Continue reading "(28 Jan 2021) Tocilizumab- incidence of secondary nosocomial infections was high"

Month: February 2021

(01 Feb 2021) Tocilizumab- associated with reduced mortality and faster clinical improvement in patients with higher IL-6

(30 Jan 2021) Tocilizumab- study supports the use of tocilizumab in COVID-19 ARDS patients

(29 Jan 2021) Corticosteroids- showed a statistically significant decrease in mortality

(28 Jan 2021) Tocilizumab- incidence of secondary nosocomial infections was high